Additionally, YB-1 expression in breast cancer has been studied intensively, where strong clinical evidence suggests that YB-1 protein expression and its translocation from the cytoplasm to the nucleus is linked with tumour progression and could be used as an independent biomarker for aggressive breast cancer across all subtypes (Habibi et al, 2008). Here, YBX1 is linked to neoplasm.